84 results
8-K
EX-1.1
SLNO
Soleno Therapeutics Inc
7 May 24
Soleno Therapeutics Announces Pricing of Approximately $138 Million Public Offering of Common Stock
5:28pm
or other legal or governmental proceeding or other litigation or arbitration, domestic or foreign, pending to which the Company or any Subsidiary is a party … , litigation or arbitration is threatened or contemplated; and the defense of all such proceedings, litigation and arbitration against or involving the Company
S-3ASR
SLNO
Soleno Therapeutics Inc
2 Jan 24
Automatic shelf registration
4:06pm
of their fiduciary duties. They may also reduce the likelihood of derivative litigation against the registrant’s directors and executive officers
8-K
EX-1.2
n4vgvy0utob4 cia52om
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-10.1
ptj6cge45vhnp514v
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
8-K
EX-1.1
hb248ulq
29 Sep 23
Entry into a Material Definitive Agreement
4:55pm
424B5
qlv0o
29 Sep 23
Prospectus supplement for primary offering
4:51pm
424B5
0bena7vg
27 Sep 23
Prospectus supplement for primary offering
5:26pm
8-K
EX-10.1
j6mr54jntywhkkzmv7
19 Dec 22
Soleno Therapeutics Announces Financing Commitment for up to $60 Million
4:49pm